BioSpace
✓

BioSpace
Listen Score
LS 30
Global Rank
TOP 10%

OM DENNE PODCAST 🔗

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Videnskab
Biovidenskab
Værter:
Opdateringsfrekvens:
semiweekly
Gennemsnitlig lydlængde:
20 minutes
Gæsteinterviews
Engelsk
USA
274 episoder
siden 8. november 2023
episodic
BrugAPItil at hente denne podcast iJSON

I DENNE PODCAST 🔗

Redigér disse tags

SENESTE EPISODE 🔗

Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

· udskrift
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and cou…
00:24:18
DEL
GEM

SØG BLANDT TIDLIGERE EPISODER

Søg efter gamle afsnit af BioSpace.
Integrer denne søgefelt på dit websted

SIDSTE EPISODER

The race for access: How the FAIR Act could reclaim U.S. biotech leadership

The race for access: How the FAIR Act could reclaim U.S. biotech leadership

· udskrift
In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help …
00:20:28
DEL
GEM
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

· udskrift
Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimm…
00:20:09
DEL
GEM
How radioligand therapy is rewriting cancer care

How radioligand therapy is rewriting cancer care

· udskrift
In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We examine radioligand therapy’s accelerating momentum and how its diagnostic and therapeuti…
00:15:38
DEL
GEM
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz

Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz

· udskrift
Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to turn things around; Viking Therapeutics and Roche report positive results for their weight loss assets…
00:21:21
DEL
GEM
When vision fades: Rethinking wet AMD and the durability gap

When vision fades: Rethinking wet AMD and the durability gap

· udskrift
In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer at Valitor. We talk about the eye condition call wet age-related macular degeneration (AMD…
00:21:35
DEL
GEM
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

· udskrift
The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its TrialBlazer initiative. Meanwhile, Definium Therapeutics notched ano…
00:22:11
DEL
GEM
The supply chain fault lines of modern pharma

The supply chain fault lines of modern pharma

· udskrift
In this episode of Denatured, sponsored by SK Pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode, we discuss how CDMOs are revamping supply‑chain strategy for a new generation of intricate modalities. Topics addressed include mov…
00:36:20
DEL
GEM
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease

Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease

· udskrift
September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in P…
00:20:19
DEL
GEM
Breaking borders: Building biotech scale in Benelux

Breaking borders: Building biotech scale in Benelux

· udskrift
In this episode of Denatured, you’ll listen to Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We examine why Benelux delivers world‑class science yet remains an investment patchwork, and what it will take to knit the regio…
00:18:34
DEL
GEM
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra BioSpace, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
PODCAST SØGEMOTOR
Du kan bruge vores hjemmeside til at søge efter3,821,009podcasts og195,286,681episoder efter personer, steder eller emner.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of giants.  ‐ Isaac "Llamacorn" Newton

ANBEFALINGER

Brug API til at hente denne podcast